Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Citron Research

Short Seller Andrew Left Says 'OpenAI At $500 Billion Puts Palantir At $40' — And That's Generous

Renowned short-seller Andrew Left's Citron Research has issued a bearish report on Palantir Technologies Inc. (NASDAQ:PLTR), arguing the stock is significantly overvalued and its price is "detached from fundamentals and analysis".

Benzinga

Citron Research Just Warned AGAIN on Palantir. How Should You Play PLTR Stock Here?

Citron Research says Palantir stock at $40 per share would still be an expensive AI stock to own. Wall Street recommends caution on PLTR shares as well.

Barchart

Short Seller Slams Jim Cramer Over Palantir, Accuses Him Of Hyping 'High-Multiple, Hype-Driven Narrative' After $200 Price Target Call

Famed short-seller Andrew Left's Citron Research publicly challenged CNBC's Jim Cramer over his bullish stance on Palantir Technologies Inc. (NASDAQ:PLTR).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

GameStop Short Seller Andrew Left Is Taking On Retail Investors Again, Now Says Palantir Stock Is 'Beyond Overvalued'

Citron Research founder and famed short seller Andrew Left announced a new short pick on Wednesday during an appearance on Fox Business.

Benzinga

Andrew Left Doubles Down On Rocket Companies: 'This Isn't A Meme,' It's A 'Housing Juggernaut' In The Making (CORRECTED)

Editor's Note: This article has been updated to correct the individual’s name in the headline.

Benzinga

Teladoc Stock Is a ‘Coiled Spring’ That Could Surge Higher. Should You Buy TDOC Here?

Teladoc stock gains as Citron Research posts a bullish report in its favor. Wall Street remains positive on TDOC shares for the second half of 2025 as well.

Barchart

Teladoc Health Stock Jumps After Citron Research Calls It A 'Coiled Spring'

Teladoc Health Inc (NYSE:TDOC) shares are rising Monday after Citron Research made positive comments about the company on its X account.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Citron Research Just Identified This 1 Stock to Buy as a ‘Hidden’ AI Winner

Former short seller Citron Research is growing bullish on Teladoc's growth potential.

Barchart

Andrew Left's Citron Research Says Nvidia-Backed Nebius Is The Next 'AI Wall Street Darling' — Stock Moves Up 14%

Shares of Nebius Group NV (NASDAQ:NBIS) jumped 13.90% on Tuesday after Citron Research highlighted the company’s potential to become the next artificial intelligence sensation on Wall Street, citing its deep ties with NVIDIA Corp. (NASDAQ:

Benzinga

Here's How High MicroStrategy Stock Can Climb as Bitcoin Races to New Highs

In the past five years, MicroStrategy's massive exposure to Bitcoin has allowed share prices to surge over 2,000%. Can the tech stock continue to surge in 2025?

Barchart

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its Phase 3 trial.

Benzinga

Short Seller Andrew Left Charged With Securities Fraud Scheme

Short seller Andrew Left charged with securities fraud for manipulating stock prices through Citron Research. SEC also pursuing charges in a million fr...

Top News

Short-seller Andrew Left is betting against GameStop again, undaunted by his 100% loss last time

When meme-stock traders' de facto leader posted a screenshot implying he owns over $100 million of GameStop, Andrew Left immediately shorted the stock.

Fortune

Citron Research Founder Andrew Left Lives In Fear Amidst GameStop Fallout

Left worries about potential charges as federal agencies probe activist short sellers

Zenger

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why This Short Seller Is Doubling Down Against Cryptocurrency, Says 'US Government Should Be Embarrassed' About FTX Debacle

Activist investor and short seller Citron Research made headlines in 2021 for attacking stocks like GameStop Corporation (NYSE: GME) and other popular companies with the retail investment crowd.

Benzinga

Crypto Bull Kevin O'Leary Vs. Bear Andrew Left: Who Will Win The Tug of War?

Even as the cryptocurrency market on Monday reclaimed the $1 trillion market cap following a dramatic fall in prices of late, there could be more pain ahead for investors in the short term, according to experts.

Benzinga

EXCLUSIVE: Short Seller Andrew Left Says The Idea Of Decentralization Is The 'Stupidest Thing Ever'

Andrew Left, founder of Citron Research says the idea of decentralization, where power is shifted from the hands of centralized entities is the “stupidest thing ever” and pointed out that the only utility Bitcoin has is that it is a collective consciousness of people, with people buying because others are.

Benzinga

Citron Research Targets Bitcoin, Ethereum, NFTs After Staying On Sidelines For 18 Months

A well-known figure from the David vs. Goliath story involving video game retailer GameStop Corp (NYSE: GME) that pitted retail traders against hedge funds and short-sellers has sights set on the cryptocurrency investors.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

'Diamond Hands: The Legend Of WallStreetBets' Dives Into GameStop & AMC Squeeze: Here's What To Know About The Film's Premiere

MSNBC Films, NBC News Studios, and ZCDC Films will premiere “Diamond Hands: The Legend of WallStreetBets” Sunday, May 15 at 10 p.m. EDT on MSNBC. What To Know: The documentary launch comes more than a year after retail traders on online forums like WallStreetBets clashed with famed fundamentalists like Citron…

Benzinga

Could Peloton Buy Blue Apron? Here's Why Citron's Andrew Left Says Yes

Peloton Interactive Inc (NASDAQ: PTON) could purchase meal kit service Blue Apron Holdings Inc (NYSE: APRN), Citron Research analyst Andrew Left said in a Tuesday note.&nbs

Benzinga

Andrew Left: 'Things Have Changed For Short Sellers'

Investor Andrew Left was one of the central figures of the GameStop Corp (NYSE: GME) storyline in 2021. One year later, Left shared his thoughts on how things have changed for short sellers.

Benzinga

Here's Why Blue Apron Is Trading Higher Today

Andrew Left's Citron Research issued a lengthy research report on Blue Apron Holdings Inc (NYSE:APRN) with a $40 price target. The price target implies a 443% upside to the January 19 closing price of $7.36. "There are hundreds of meal kit reviews online, and Blue Apron is always at the top of the list on food…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.